Substantial Expansion and Awareness of Alzheimer’s Drugs Market

As per latest analysis from the Transparency Market Research (TMR), the global expansion and awareness of the Alzheimer’s drugs market are expected to exhibit a consistent 7.5% CAGR in the 2017-2025 forecast period.

Due to lack of awareness about the disease in many of the underdeveloped countries, has made crucial for global Alzheimer’s drugs market players in emerging regions for the wide scope.

However, these market players located in developed regions such as Europe and North America are likely to lead the global Alzheimer’s drugs market in the coming years due to the widespread availability of Alzheimer’s treatment channels in countries such as the U.K., U.S., Germany, and Canada. The other key players in the global Alzheimer’s drugs market include Merz Holding GmbH & Co KG, Johnson & Johnson, Eisai Co Limited, H Lundbeck A/S, Daiichi Sankyo Company Limited, and Ono Pharmaceutical Co Limited beyond Allergan and Novartis as mentioned above.

It was primarily dominated by the Allergan plc and Novartis AG in 2016, with their global market prospects of the Alzheimer’s drugs market for 2017-2021 with the other leading emerging brands.

As per the Transparency Market Research (TMR) Quantitative Analysis, in 2017 the Alzheimer’s drugs market revenue was valued more than US$3.6 billion and by 2025 it is expected to rise to US$6.4 billion. In the 2017-2025 forecast period, it is expected to exhibit a consistent 7.5% CAGR.

Global Alzheimer’s drugs market likely to dominates by the memantine

By drug class, the global Alzheimer’s drugs market is segmented into memantine, cholinergic, combined drugs, and others. In the coming years, beyond all these memantine is likely to endure the leading contributor to the global Alzheimer’s drugs market, due to the paucity of effective drug classes primarily in several developing regions. Combined drug treatment is also likely to endure a key contributor to the global Alzheimer’s drugs market in the coming years due to the growing recognition of its efficacy and rising availability in developed countries.

In the coming years, North America is likely to stand as the leading regional segment of the global Alzheimer’s drugs market. The North America Alzheimer’s drugs market garnered revenue of US$1.7 billion in 2017 and is likely to increase to more than US$3 billion by 2025 at a steady CAGR of 7.3%. On the other hand, The Asia Pacific Alzheimer’s drugs market is likely to illustrate the highest CAGR, at 8.6%, in the 2017-2025 forecast period, with the region expected to rise from a revenue valuation of US$1.1 billion to close to US$2.3 billion there in.

Growing prevalence of Alzheimer’s will propel Alzheimer’s drugs market in developed countries

In developed Western countries, the prime driver for the global Alzheimer’s drugs market is the rising prevalence of the disease. In recent years, several neurodegenerative diseases have raised in prevalence in countries such as the U.S., leading to steady government support for drug development. This has resulted in highly good conditions for the Alzheimer’s drugs market in North America, which leads to the steady growth of the market in countries such as the U.S.

However, In developing regions such as Asia Pacific the rising awareness about neurodegenerative diseases is likely to be a key contributor to the global Alzheimer’s drugs market in the coming years. Awareness about the Alzheimer’s disease stays limited in several countries in southeast Asia, which has resulted in unsupportive research infrastructure and unstable healthcare systems. Due to the high prices of advanced Alzheimer’s drugs in underdeveloped countries in Asia Pacific have also held back the Alzheimer’s drugs market. In the coming years, in several developing Asia Pacific countries the growing support for mental care infrastructure from governments is thus likely to drive the Alzheimer’s drugs market in the region.

More Resources:

ADHD Drugs Raise Risk Of Heart Defects In Babies

Best API Manufacturers In India

Hepatitis B Vaccine

Reduction Of Antibiotic Prescriptions Through Physician Education And Intervention

FDA Approves Pill With Sensor Having A Digital Ingestion Tracking System

LEAVE A REPLY

Please enter your comment!
Please enter your name here

five × three =